
Xintela Investor Relations Material
Latest events

Q1 2025
23 May, 2025

Q4 2024
28 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Xintela
Access all reports
Xintela AB is a Sweden-based biomedical company specializing in regenerative medicine and cancer treatments. The company focuses on developing therapies for cartilage damage and osteoarthritis using its proprietary XINMARK technology, which identifies specific stem cells that can develop into cartilage cells. In oncology, Xintela is working on targeted treatments for aggressive cancers, including glioblastoma. Through its subsidiary Targinta, the company also develops antibody-based therapies targeting cancer cells. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
XINT
Country
🇸🇪 Sweden